Publication

Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging

van Waarde, A., Dierckx, R. A. J. O., Zhou, X., Khanapur, S., Tsukada, H., Ishiwata, K., Luurtsema, G., de Vries, E. F. J. & Elsinga, P. H., Jan-2018, In : Medicinal research reviews. 38, 1, p. 5-56 52 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

van Waarde, A., Dierckx, R. A. J. O., Zhou, X., Khanapur, S., Tsukada, H., Ishiwata, K., ... Elsinga, P. H. (2018). Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging. Medicinal research reviews, 38(1), 5-56. https://doi.org/10.1002/med.21432

Author

van Waarde, Aren ; Dierckx, Rudi A. J. O. ; Zhou, Xiaoyun ; Khanapur, Shivashankar ; Tsukada, Hideo ; Ishiwata, Kiichi ; Luurtsema, Gert ; de Vries, Erik F. J. ; Elsinga, Philip H. / Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging. In: Medicinal research reviews. 2018 ; Vol. 38, No. 1. pp. 5-56.

Harvard

van Waarde, A, Dierckx, RAJO, Zhou, X, Khanapur, S, Tsukada, H, Ishiwata, K, Luurtsema, G, de Vries, EFJ & Elsinga, PH 2018, 'Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging', Medicinal research reviews, vol. 38, no. 1, pp. 5-56. https://doi.org/10.1002/med.21432

Standard

Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging. / van Waarde, Aren; Dierckx, Rudi A. J. O.; Zhou, Xiaoyun; Khanapur, Shivashankar; Tsukada, Hideo; Ishiwata, Kiichi; Luurtsema, Gert; de Vries, Erik F. J.; Elsinga, Philip H.

In: Medicinal research reviews, Vol. 38, No. 1, 01.2018, p. 5-56.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

van Waarde A, Dierckx RAJO, Zhou X, Khanapur S, Tsukada H, Ishiwata K et al. Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging. Medicinal research reviews. 2018 Jan;38(1):5-56. https://doi.org/10.1002/med.21432


BibTeX

@article{1bb002e9a9294adab5767ec723924c99,
title = "Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging",
abstract = "Adenosine A2A receptors (A2ARs) are highly expressed in the human striatum, and at lower densities in the cerebral cortex, the hippocampus, and cells of the immune system. Antagonists of these receptors are potentially useful for the treatment of motor fluctuations, epilepsy, postischemic brain damage, or cognitive impairment, and for the control of an immune checkpoint during immunotherapy of cancer. A2AR agonists may suppress transplant rejection and graft-versus-host disease; be used to treat inflammatory disorders such as asthma, inflammatory bowel disease, and rheumatoid arthritis; be locally applied to promote wound healing and be employed in a strategy for transient opening of the blood–brain barrier (BBB) so that therapeutic drugs and monoclonal antibodies can enter the brain. Increasing A2AR signaling in adipose tissue is also a potential strategy to combat obesity. Several radioligands for positron emission tomography (PET) imaging of A2ARs have been developed in recent years. This review article presents a critical overview of the potential therapeutic applications of A2AR ligands, the use of A2AR imaging in drug development, and opportunities and limitations of PET imaging in future research.",
keywords = "Positron emission tomography (PET) imaging, adenosine A(2A) receptors, antagonists, agonists, drug development, POSITRON-EMISSION-TOMOGRAPHY, BLOOD-BRAIN-BARRIER, CENTRAL-NERVOUS-SYSTEM, EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS, SPONTANEOUSLY HYPERTENSIVE-RATS, INFLAMMATORY-BOWEL-DISEASE, AMYGDALA-KINDLED SEIZURES, PERMANENT FOCAL ISCHEMIA, LUNG REPERFUSION INJURY, WORKING-MEMORY DEFICITS",
author = "{van Waarde}, Aren and Dierckx, {Rudi A. J. O.} and Xiaoyun Zhou and Shivashankar Khanapur and Hideo Tsukada and Kiichi Ishiwata and Gert Luurtsema and {de Vries}, {Erik F. J.} and Elsinga, {Philip H.}",
note = "{\circledC} 2017 Wiley Periodicals, Inc.",
year = "2018",
month = "1",
doi = "10.1002/med.21432",
language = "English",
volume = "38",
pages = "5--56",
journal = "Medicinal research reviews",
issn = "0198-6325",
publisher = "Wiley",
number = "1",

}

RIS

TY - JOUR

T1 - Potential Therapeutic Applications of Adenosine A2A Receptor Ligands and Opportunities for A2A Receptor Imaging

AU - van Waarde, Aren

AU - Dierckx, Rudi A. J. O.

AU - Zhou, Xiaoyun

AU - Khanapur, Shivashankar

AU - Tsukada, Hideo

AU - Ishiwata, Kiichi

AU - Luurtsema, Gert

AU - de Vries, Erik F. J.

AU - Elsinga, Philip H.

N1 - © 2017 Wiley Periodicals, Inc.

PY - 2018/1

Y1 - 2018/1

N2 - Adenosine A2A receptors (A2ARs) are highly expressed in the human striatum, and at lower densities in the cerebral cortex, the hippocampus, and cells of the immune system. Antagonists of these receptors are potentially useful for the treatment of motor fluctuations, epilepsy, postischemic brain damage, or cognitive impairment, and for the control of an immune checkpoint during immunotherapy of cancer. A2AR agonists may suppress transplant rejection and graft-versus-host disease; be used to treat inflammatory disorders such as asthma, inflammatory bowel disease, and rheumatoid arthritis; be locally applied to promote wound healing and be employed in a strategy for transient opening of the blood–brain barrier (BBB) so that therapeutic drugs and monoclonal antibodies can enter the brain. Increasing A2AR signaling in adipose tissue is also a potential strategy to combat obesity. Several radioligands for positron emission tomography (PET) imaging of A2ARs have been developed in recent years. This review article presents a critical overview of the potential therapeutic applications of A2AR ligands, the use of A2AR imaging in drug development, and opportunities and limitations of PET imaging in future research.

AB - Adenosine A2A receptors (A2ARs) are highly expressed in the human striatum, and at lower densities in the cerebral cortex, the hippocampus, and cells of the immune system. Antagonists of these receptors are potentially useful for the treatment of motor fluctuations, epilepsy, postischemic brain damage, or cognitive impairment, and for the control of an immune checkpoint during immunotherapy of cancer. A2AR agonists may suppress transplant rejection and graft-versus-host disease; be used to treat inflammatory disorders such as asthma, inflammatory bowel disease, and rheumatoid arthritis; be locally applied to promote wound healing and be employed in a strategy for transient opening of the blood–brain barrier (BBB) so that therapeutic drugs and monoclonal antibodies can enter the brain. Increasing A2AR signaling in adipose tissue is also a potential strategy to combat obesity. Several radioligands for positron emission tomography (PET) imaging of A2ARs have been developed in recent years. This review article presents a critical overview of the potential therapeutic applications of A2AR ligands, the use of A2AR imaging in drug development, and opportunities and limitations of PET imaging in future research.

KW - Positron emission tomography (PET) imaging

KW - adenosine A(2A) receptors

KW - antagonists

KW - agonists

KW - drug development

KW - POSITRON-EMISSION-TOMOGRAPHY

KW - BLOOD-BRAIN-BARRIER

KW - CENTRAL-NERVOUS-SYSTEM

KW - EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS

KW - SPONTANEOUSLY HYPERTENSIVE-RATS

KW - INFLAMMATORY-BOWEL-DISEASE

KW - AMYGDALA-KINDLED SEIZURES

KW - PERMANENT FOCAL ISCHEMIA

KW - LUNG REPERFUSION INJURY

KW - WORKING-MEMORY DEFICITS

U2 - 10.1002/med.21432

DO - 10.1002/med.21432

M3 - Review article

VL - 38

SP - 5

EP - 56

JO - Medicinal research reviews

JF - Medicinal research reviews

SN - 0198-6325

IS - 1

ER -

ID: 39474269